Although the U.S. Food and Drug Administration has taken an active role in extending guidance on the conduct of decentralized clinical trials (DCTs), the industry hasn't seen yet the scale of their adoption hoped for by many because of lack of trust in sites' abilities to handle such trials on the part of sponsors. This session explores two different site networks and at a high level, with an emphasis on how they and their sponsors worked to comply with regulatory guidance in two different DCT study designs.

CEU: 1.00 ACRP

Speaker:

Noelle Gaskill, Head of Clinical Research Collaborations, Mirati Therapeutics

Related Blog Content:

A Success Story of a Site-Centric Approach to Hybrid DCTs

Watch a Sneak Peek into the Session Content: